The Competition

Opportunity

The Competition

There is no effective drug available with the dual effect of both antibacterial and anti-inflammatory. The benchmark treatment options are antibiotics and topical treatments based on anti-infective components (iodine, silver, PHMB). Each of these treatments have built-in risks, either for the patient, the environment or both. A peptide such as TCP-25, identical to the ones in the body’s own defence system is very likely to neither cause bacterial resistance nor have any negative side effects for the patient or the environment.

		Anti-infective	Broad spectrum	Anti-inflammatory	Anti-coagulative	Endotoxin blocking	Risks
Antibiotics		Yes	No	No	No	No	Resistance development Toxicity (some)
Antiseptics	Silver	Yes	Yes	No	No	No	Toxicity Environmentally harmful
	PHMB	Yes	Yes	No	No	No	Carcinogenic
	Triclosan	Yes	Yes	No	No	No	Toxic and Carcinogenic Hormone-disturbing Environmentally Harmful
	TCP-25	Yes	Yes	Yes	Yes	Yes	Low

		Anti-infective	Broad spectrum	Anti-inflammatory	Anti-coagulative	Endotoxin blocking	Risks
Antibiotics		Yes	No	No	No	No	Resistance development Toxicity (some)
Antiseptics	Silver	Yes	Yes	No	No	No	Toxicity Environmentally harmful
	PHMB	Yes	Yes	No	No	No	Carcinogenic
	Triclosan	Yes	Yes	No	No	No	Toxic and Carcinogenic Hormone-disturbing Environmentally Harmful
	TCP-25	Yes	Yes	Yes	Yes	Yes	Low